PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.13
D/E less than half of TRVN's 0.25. Charlie Munger would verify if this conservative approach provides competitive advantages.
2.00
Much higher net debt at 1.25-1.5x TRVN's 1.45. Bill Ackman would demand clear deleveraging catalysts.
No Data
No Data available this quarter, please select a different quarter.
2.63
Current ratio 75-90% of TRVN's 3.31. Bruce Berkowitz would look for working capital optimization opportunities.
No Data
No Data available this quarter, please select a different quarter.